US Patent

US12005043 — Formulations of AG10

Method of Use · Assigned to Eidos Therapeutics Inc · Expires 2039-08-16 · 13y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects high-load tablet formulations of AG10 or a pharmaceutically acceptable salt thereof, including at least 40% AG10 by weight and various pharmaceutical excipients.

USPTO Abstract

The present disclosure provides high-load tablet formulations of AG10 or a pharmaceutically acceptable salt thereof. In some aspects, provided herein are table formulations of AG10 or a pharmaceutically acceptable salt thereof that include at least 40% or more AG10 by weight and at least one pharmaceutical excipient selected from one or more fillers, one or more binders, one or more disintegrants, and one or more lubricants.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-4046 — acoramidis-hydrochloride

Patent Metadata

Patent number
US12005043
Jurisdiction
US
Classification
Method of Use
Expires
2039-08-16
Drug substance claim
No
Drug product claim
Yes
Assignee
Eidos Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.